Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Deconstructing the Role of MALAT1 in MAPK-Signaling in Melanoma

News

May 30, 2023
PRESS RELEASE: On May 26, 2023, a new research paper was published in Oncotarget, entitled, “Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment.” continue reading »

Can the Creatine Shuttle be Targeted to Fight Colorectal Cancer?

Oncotarget

May 25, 2023
In a new study, researchers investigated the creatine shuttle pathway as a potential therapeutic target in colorectal cancer cells. continue reading »

Behind the Study: Molecular Dialogue Between Tumor Cells and Fibroblasts

Oncotarget

May 25, 2023
Dr. Gopal C. Kundu from KIIT Deemed to be University in Odisha, India, describes a recent editorial he co-authored that was published by Oncotarget in Volume 14, entitled, “The molecular dialogue between the tumor cells and fibroblasts.” continue reading »

HER3: Survival Pathway and Therapeutic Target in Metastatic Colorectal and Pancreatic Cancer

News

May 24, 2023
PRESS RELEASE: On May 10, 2023, a new research perspective was published in Oncotarget, entitled, “HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma.” continue reading »

GPR141 Regulates Breast Cancer Progression via Oncogenic Mediators and The p-mTOR/p53 Axis

News

May 22, 2023
PRESS RELEASE: On May 19, 2023, a new research paper was published in Oncotarget, entitled, “G-protein-coupled receptor 141 mediates breast cancer proliferation and metastasis by regulating oncogenic mediators and the p-mTOR/p53 axis.” continue reading »